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Abstract
Background: Aberrations in the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR)/AKT pathway
are common in solid tumors. Numerous drugs have been developed to target different components of this pathway.
However the prognostic value of these aberrations is unclear.
Methods: PubMed was searched for studies evaluating the association between activation of the PI3K/mTOR/AKT pathway
(defined as PI3K mutation [PIK3CA], lack of phosphatase and tensin homolog [PTEN] expression by immunohistochemistry
or western-blot or increased expression/activation of downstream components of the pathway by immunohistochemistry)
with overall survival (OS) in solid tumors. Published data were extracted and computed into odds ratios (OR) for death at 5
years. Data were pooled using the Mantel-Haenszel random-effect model.
Results: Analysis included 17 studies. Activation of the PI3K/mTOR/AKT pathway was associated with significantly worse 5-
year survival (OR:2.12, 95% confidence intervals 1.42–3.16, p,0.001). Loss of PTEN expression and increased expression/
activation of downstream components were associated with worse survival. No association between PIK3CA mutations and
survival was observed. Differences between methods for assessing activation of the PI3K/mTOR/AKT pathway were
statistically significant (p = 0.04). There was no difference in the effect of up-regulation of the pathway on survival between
different cancer sites (p = 0.13).
Conclusion: Activation of the PI3K/AKT/mTOR pathway, especially if measured by loss of PTEN expression or increased
expression/activation of downstream components is associated with poor survival. PIK3CA mutational status is not
associated with adverse outcome, challenging its value as a biomarker of patient outcome or as a stratification factor for
patients treated with agents acting on the PI3K/AKT/mTOR pathway.
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Introduction
Historically, the development of anti-neoplastic drugs has not
focused on the targeting of specific molecular aberrations [1].
However, more recently, some targeted drugs have been
developed against known oncogenes in selected patient popula-
tions. Examples of this are trastuzumab for HER2 over-expressing
or amplified breast and gastric cancer [2,3], imatinib for chronic
myeloid leukemia (CML) [4], vemurafenib for metastatic melano-
ma with (V600E) B-RAF mutations and crizotinib for non-small
cell lung cancer patients with anaplastic lymphoma kinase (ALK)
rearrangements [5,6]. In these examples, development of the drug
was carried out in parallel with the identification of a biomarker
that permitted the selection of patients with a higher chance of
response.
The discovery and validation of biomarkers has become an
integral part of successful drug development, with few drugs under
development lacking associated biomarker programs. Such bio-
markers are typically biological surrogates that can guide in the
identification of patients with a higher probability of response. A
biomarker can be a known oncogenic alteration like a gene
mutation, an overexpressed protein or a protein that reflects the
activation status of a signaling pathway [7]. Other types of
biomarkers may help monitoring response to treatment or provide
information about prognosis and outcome [7]. In this latter case,
markers associated with worse outcome can be informative of a
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more aggressive phenotype potentially guiding the selection of
more intensive treatment [8].
The phosphatidylinositol 3-kinase (PI3K)/mammalian target of
rapamycin (mTOR)/AKT pathway has been linked to the
pathophysiology of several neoplastic diseases [9,10]. Activation
of this pathway can be a result of mutations in the PI3K or AKT
genes, loss of phosphatase and tensin homolog (PTEN), or
constitutive activation of upstream regulatory pathways such as
receptor tyrosine kinases (Figure 1) [9,10]. Given the pro-
oncogenic role of the PI3K/AKT/mTOR pathway in cancer, it
has become a target of interest for drug development. Inhibition of
mTOR with rapalogs has shown clinical efficacy against some
solid tumors, including everolimus for angiomyolipoma associated
with tuberous sclerosis, metastatic renal cell carcinoma, breast
cancer, or pancreatic neuroendocrine carcinomas and temsiroli-
mus for renal cell carcinoma [11–14]. Many other agents in
clinical development are designed to inhibit the PI3K/AKT/
mTOR pathway at different levels and include pure PI3K
inhibitors, dual PI3K-mTOR inhibitors, AKT inhibitors or
mTOR inhibitors [15,16]. Despite the approval of some drugs
and the clinical development of other agents targeting the PI3K/
AKT/mTOR pathway, little is known about which patients are
more likely to benefit from targeting this pathway. Similarly, the
relationship between alterations of this pathway and a more
aggressive phenotype is unclear.
Here we report a systematic review and meta-analysis of studies
assessing the association of activation of the PI3K/AKT/mTOR
pathway and clinical outcome in solid tumors.
Methods
Identification and selection of studies
This analysis was conducted in line with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
guidelines [17]. Medline (Host: PubMed) was searched for studies
published between January 2002 and December 2012, which
evaluated the expression of components of the PI3K/AKT/
mTOR pathway and survival in solid tumors. We used the MeSH
terms ‘‘PIK3CA and cancer’’ and ‘‘PIK3CA-mTOR and cancer’’
and ‘‘PTEN loss and cancer’’ adding the limitation of human
studies. In addition we used the entry ‘‘PIK3CA or mTOR’’ and
the name of each specific solid tumor (e.g. PIK3CA or mTOR and
breast cancer) to recognize additional studies. The search was
restricted to publications in English. Additional studies were
identified through reviews of citation lists (Figure S1 and figure
S2). Eligibility criteria were the availability of survival data for at
least 5 years in relation to three types of pathway aberrations;
mutations in the PI3K gene in any domain as measured by
polymerase chain reaction (PCR) or other genomic techniques, the
lack of PTEN expression by immunohistochemistry (IHC) or
western-blot, or the evaluation of downstream components of the
pathway like phospho-S6, mTOR, phospho-mTOR, AKT or
phospho-4EBP1 by IHC. Studies reporting outcome of patients
who had received a specific targeted agent against the PI3K/
AKT/mTOR pathway or related pathways were excluded as were
studies reporting only disease free survival or cancer-specific
survival.
Data Extraction
Two authors (VSC and AO) extracted information indepen-
dently using pre-prepared data abstraction forms. The following
details were extracted: tumor type, number of patients, duration of
follow-up, mechanism for activation of PI3K/AKT/mTOR
pathway (PI3K mutation, activation of mTOR/AKT or PTEN
loss), methods used for the evaluation of pathway activation, and
cut-off used for defining pathway activation. The outcome of
interest was five-year overall survival (OS). In all cases, survival
data were estimated from Kaplan-Meier curves independently by
two authors (FV and MA).
Data Synthesis
The effect of any aberration in the pathway on overall survival
was analyzed initially. Subsequently subgroup analyses were
conducted to explore the relationship between survival and
different components of the PI3K/AKT/mTOR pathway that
were evaluated in each study. Group one was termed ‘‘mTOR or
AKT activation’’ and included studies that evaluated downstream
components of the pathway including phosphorylated proteins
such as mTOR, AKT, S6, and others (see table 1). Group two was
termed ‘‘PIK3CA mutations’’ and included those studies that
Figure 1. Schematic representation of the PI3K/mTOR pathway.
doi:10.1371/journal.pone.0095219.g001
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evaluated mutations in the PI3K gene. The third included studies
that evaluated loss of PTEN as measured by IHC. A second
subgroup analysis included assessment based on the primary
cancer site.
Statistical analysis
The proportion of patients surviving 5 years was estimated from
the Kaplan-Meier curves for both normal (control group) and the
presence of the molecular alteration (experimental group). The
relative frequency of survival at 5 years between the control and
experimental groups was expressed as an odds ratio (OR) and its
95% confidence interval (CI). Data were combined into a meta-
analysis using RevMan 5.1 analysis software (Cochrane Collabo-
ration, Copenhagen, Denmark). Estimates of ORs were weighted
and pooled using the Mantel-Haenszel method. Cochran’s Q (p,
0.10) and the I2 index (.50%) were used to define inter-study
heterogeneity. Due to significant heterogeneity, random effects
modeling was used for all analyses. Analyses were conducted for all
studies and differences between the subgroups were assessed using
methods described by Deeks et al. [18]. All statistical tests were
two sided, and statistical significance was defined as p,0.05. No
corrections were made for multiple comparisons.
Results
Description of studies
We identified 17 studies that evaluated activation of the PI3K/
mTOR/AKT pathway and survival in solid tumors. These studies
comprised a total of 4746 patients with a median sample size of
279 patients. The characteristics of included studies are shown in
table 1. Six studies evaluated the expression of the PI3K/AKT/
mTOR pathway in breast cancer, five in gastrointestinal tumors,
three in gynecological cancers, and one each in prostate, non-small
cell lung cancer (NSCLC) and oropharyngeal cancers. Six studies
were included in the group called ‘‘mTOR or AKT activation’’,
six in the ‘‘PIK3CA mutation’’ group and five in the ‘‘PTEN loss’’
group. The estimated median follow-up was 4.3 years (range= 2.6
to 16 years). The prevalence of pathway activation and the
methods used for the analyses of molecular alterations of this
pathway are shown in Table 2.
Association of activation of PI3K/AKT/mTOR pathway and
survival
Overall, there was an association between the presence of
molecular alterations in the PI3K/AKT/mTOR pathway and
worse 5-year survival (OR 2.12; 95% CI 1.42–3.16, p,0.001)
(Figure 2). There was significant inter-study heterogeneity
(Cochran’s Q p,0.001, I2 = 84%).
Association of pathway activation and survival by tumor
type
Studies in gastrointestinal tumors (n = 5) and gynecologic
cancers (n = 3) showed a numerically higher association with
worse survival (OR 2.51; 95% CI 1.83–3.43 and OR 4.78; 95%
CI 1.14–20.1, respectively) compared with studies in breast cancer
(n = 6) and other solid tumors (NSCLC, prostate and oropharyn-
geal, [n= 3]) which showed no association (OR 1.43; 95% CI
0.74–2.79 and OR 1.08; 95% CI 0.44–2.67, respectively). Of
interest, in the one study in prostate cancer, there was a large
magnitude of effect on survival (OR 7.51, 95% CI 0.98–57.74),
but there was no obvious effect seen in studies of NSCLC and
orophayngeal cancer (OR 0.73, 95% 0.52–1.03 and 0.85, 95% CI
0.30–2.37, respectively). However, these differences did not meet
statistical significance (subgroup difference p= 0.13).
Association of pathway activation and survival by type of
activation
The results of the subgroup analysis based on the specific part of
the PI3K/AKT/mTOR pathway are shown in figure 3. For
studies assessing PIK3CA gene mutations (n = 6), there was no
association with worse 5-years survival (OR: 1.24; 95% CI 0.70–
2.20, p = 0.46). In contrast, among studies evaluating activated
Table 1. Characteristics of included studies.
Article Group Subtype Tumor Subtype Follow-up time
Barbareschi, M [21] PIK3CA mutations Breast Cancer Not reported
Dong, Y [26] PIK3CA mutations Gynecological cancer Not reported
Kalinsky, K [27] PIK3CA mutations Breast Cancer Median 12.8 years (range not reported)
Stemke-Hale, K [28] PIK3CA mutations Breast Cancer Not reported
Li, SY [29] PIK3CA mutations Breast Cancer Median 4.2 years (range 0.2–6.5 years)
Lai, Y [30] PIK3CA mutations Breast Cancer Median, 6.4 years (range 0.1–9.3 years)
Kirkegaard, T [31] mTOR or AKT activation Breast Cancer Median 6.5 years (range 0.6–18.4 years)
Oh, M [32] mTOR or AKT activation Non-small Cell Lung Cancer Median 2.9 years (range 0.1–12.7 years)
Xiao, L [33] mTOR or AKT activation Gastrointestinal tumors Median 5.6 years (range 0.02–12.2 years)
Yu, Z [34] mTOR or AKT activation Head and Neck Cancer Mean 3.0 years (range not reported)
Yu, G [35] mTOR or AKT activation Gastrointestinal tumors Mean 3.1 years (1.8–6.1 years)
Castellvi, J [24] mTOR or AKT activation Gynecological cancer Mean 2.6 years (range 2.0–6.7 years)
Hsu, CP [36] PTEN loss Gastrointestinal tumors Median 4.3 years (range 0.3–6.6 years)
Lotan, LT [37] PTEN loss Prostate Cancer Median 16.0 years (range not reported)
Sawai, H [38] PTEN loss Gastrointestinal tumors Median 3.0 years (range not reported)
Sze, KM [39] PTEN loss Gastrointestinal tumors Not reported
Terakawa, N [40] PTEN loss Gynecological cancer Not reported
doi:10.1371/journal.pone.0095219.t001
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Table 2. Prevalence and analyses of the molecular alterations of the PI3K/mTOR/AKT pathway.
Article Prevalence Gene/protein Method used Cut-off or staining used
Barbareschi, M (21) N: 163; 46 missense
mutation. 24 (53%) in
exon 9 (Helicoidal); 21
(47%) in exon 20 (Kinase)
Exon 9: 12 E542K 11
E545K Exon 20: 20
H1047R
PCR amplification of exons 9 and 20 with
flanking intronic sequences and single-
strand conformation polymorphism (SSCP)
followed by sequencing of positive cases
Both are included in the Kaplan-maier.
Exon 9, helical is poor prognosis
Dong, Y (26) N: 94; 29 (30.9%) Exon 9: 28; Exon 20: 16 PCR amplifications of exon 9 and 20.
Procuts were sequenced and detected by
capillary electrophoresis.
Exon 9 E542G, A1625G; Exon 20
stp1060R, T3205A. No association with
survival
Kalinsky, K (27) N: 590; 32.5% PIK3CA mutations all
cases for the three HS
mutations
Mutation detection by Sequenom
MassARRAY system. The iPLEX Gold
Genotyping assay was used
Patients with PIK3CA H1047R mutated
tumors have significant improvement
in overall survival (P = 0.03) and breast
cancer-specific survival (P = 0.004)
Stemke-Hale, K (28) PIK3CA mutation 34.5%;
HER2: 22.7%; Basal-like
tumors: 8.3%
23 known mutations in
P3KCA
PCR and Mass spectroscopy based
approach evaluating single nucleotide
polymorfisms
No difference in kinase domain versus
all other (mainly helical domain)
Li, SY (29) N: 250 (35%); Exon 7: 3%;
Exon 9: 16%; Exon 20: 19%
PIK3CA mutations
reported in human
cancer occur in exon
7, 9 and 20
Using PCR and fluorescen t(F)-SSCP PIK3CA normal versus mutation (exon
7, 9, 20)
Lai, Y (30) N: 152 (26%) More than
half in exon 20
Mutations of PIK3CA
reported in exon 4
(codon N345I, N345K),
7 (Codon C420R), 9
(E542K, E545A, E545G,
E545G, E545K, Q546E),
20 (Codon H1047L,
H1047R, H1047Y,
H1047L, G1049R)
CR (in thermal cycler GeneAmp PCR
System 9700). PCR products were
sequenced using the ABI PRISM BigDye
Terminator v3.1 cycle sequencing kit
and 3730 DNA Analyzer
PIK3CA exon 20 mutations were
independent risk factors for overall
survival.
Kirkegaard, T (31) N: 402 ER pos. Breast
cancers.
AKT (pAKTSer-473) pan-AKT(AbcamLid, Cambridge,UK);
pAKT (Thr-308)(Cell Signallic Tecnology,
beverly, USA); pAKT(Ser-473)(Biosource
International Inc, CA,USA); Antibody
specificity was checked by western
blotting using a standard protocol
The cut-off value for high and low
levels of pAKT expression is defined as
above and below the median
histoscore.
Oh, M (32) N: 574 mTOR:
Score 0: 22%,
Score 2: 13%,
Score 3: 11%,
Score 4: 15%,
Scored 5: 17%,
Score 6: 22%.
mTor and pAKT mTOR staining: incubated with a rabbit
monoclonal antibody against mTOR
(1:100, clone 49F9). AKT: rabbit
monoclonal antibody against pAkt
(1:50, clone 736E11) Evaluated: Tumor
cells were judged as positive for pAkt
if membranous, cytoplasmic and/or
nuclear staining was present.
A semiquantitative
immunohistochemical score for
intensity of staining and the extent of
staining. Intensity, a score of 0 to 3
(corresponding to negative, weak,
moderate, and strong positivity)
Extent of staining was scored as 0
(0%), 1 (1–10%), 2 (11–50%), and 3
(51–100%), The sum of the intensity
and extent score was used as the final
score (0–6). Final score $3: positive.
Xiao, L (33) 412 gastric carcinomas,
47 adenomas, 197 non-
neoplastic mucosa.
mTOR: 66.3% of non-
neoplastic mucosa,
70.1% adenomas,61.2%
gastric carcinomas.
m-TOR , pS6 Rabbit anti-mTOR antibody (Clone ID:
Y392, 1612-1, Epitomics, USA; 1:250)
Evaluated: anti-phospho-p70 s6 kinase
(pT389, Clone ID; E175, 1175-1, Epitomics,
USA; 1:50) followed by exposure to the
anti-rabbit Envison-PO(DAKO, USA)
antibody
The positive percentage of counted
cells was graded semi-quantitatively
according to a four-tier scoring
system; negative 0–5%; weakly
positive 6–25%, moderate positive
26–50%, strongly positive 51–100%.
Yu, Z (34) p-AKT 18% p-Akt Primary antibody to p-Akt (ser 473) Cell
Signaling Technology (Beverly, MA)
AQUA scores for nuclear and
cytoplasmic p-Akt. The lowest quartile
was compared with the rest of the
cohort.
Yu, G (35) m-TOR: 50.8%; p-mTOR:
46,5%
mTOR, p-mTOR.
(prognostic factor
pmTOR)
mTOR (dilution 1:50; clone Y391; Abcam),
Evaluated: p-mTOR (Ser 2448; dilution,
1:100; clone 49F9;CST)
A semiquantitative scoring system
was used. An underexpression was
defined as no staining or staining
positivity in tumor tissue being less
than matched normal tissue, a normal
expression as staining positivity being
similar to matched normal tissue,
overexpression as staining positivity
being higher than normal tissue.
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components of mTOR or AKT (n= 6) a significant association
with worse outcome was observed (OR: 2.50; 95% CI 1.22–5.14,
p = 0.01). Similarly, studies assessing PTEN loss by IHC (n= 5)
showed a significant association with worse survival (OR 3.50;
95% CI 1.94–6.31, p,0.001). This difference between subgroups
was significant (p = 0.04).
Discussion
The identification of biomarkers that can inform the clinical
behavior of a given tumor is important for patient education and
treatment planning. In this study we explored the prognostic role
of different components of the PI3K/AKT/mTOR pathway with
the intention to identify tumors that rely on this molecular
alteration. Such information may help to guide the clinical
development of therapeutic strategies against this pathway.
Overall, there was evidence of an association between
alterations in the PI3K/AKT/mTOR pathway and poor survival.
When analyzing different components of the pathway we observed
that those studies evaluating loss of PTEN and activated
components of downstream proteins were linked with the poorest
5-years survival. Conversely, PIK3CA mutations were not linked
with worse outcome in our analysis. The fact that PTEN is a major
regulator of the activation of the PI3K pathway could explain its
association with worse outcome [19,20] as those tumors with loss
of PTEN expression could have activation of the different
components of this pathway. In contrast, although PIK3CA
mutations are considered driver mutations because they are linked
to cell survival and increased proliferation, in our study there was
no association with poor outcome [9,10]. PIK3CA mutations
compromise numerous molecular lesions including those affecting
both the catalytic and helical domains. Mutations in the helical
domain may favor the oncogenic capability of PIK3CA by
facilitating its interaction with certain signaling intermediates
linked to the transmission of pro-oncogenic signals [21]. In the
individual studies included in our analysis, mutations at different
domains were pooled and this could decrease the statistical power
needed to detect a worse outcome in this group for specific
mutations. In addition, mutations can have different functional
roles and different clinical behavior depending on the tumor type.
For example, recent studies have shown that PIK3CA mutations
are associated with different outcomes in breast cancer depending
on whether the tumor is estrogen receptor positive or negative,
and whether HER2 is over-expressed or amplified compared to
HER2-normal [22,23]. Regardless of this, the data presented
challenges the clinical relevance of PIK3CA mutations as unique
measures of PI3K/AKT/mTOR pathway activation. This is
relevant, as some ongoing clinical trials with agents that target this
pathway are using such mutational analysis as an indication of
pathway activity, with mutations being used as biomarkers for
Table 2. Cont.
Article Prevalence Gene/protein Method used Cut-off or staining used
Castellvi, J (24) p-4EBP1 (47.1%) p-4EBP1 4EBP1 Cell signaling Tech Scored the percentage of positive cells
and intensity of the staining, which
was assessed semiquantitatively.
Samples that showed any positivity
were grouped together for statistical
purposes
Hsu, CP (36) N: 133 CRC group:
89.2% R 53.4%
PTEN Primary anti-PTEN anti- body (1/200)
at room temperature for 2 h
Positive: more than 10%
Lotan, LT (37) N: 397 146 PTEN
loss (36.8%).
PTEN Rabbit monoclonal anti-PTEN
antibody(clone D4.3,-9188, cell Signaling
Technologies
Using this system, each spot of tumor
tissue was scored as negative positive
for PTEN protein by comparing
staining in malignant gland with that
of adjacent benign gland and/or
stroma which provided an internal
positive control within each tissue
core. Staining was classified as
negative if the intensity was markedly
decreased or entirely negative
Sawai, H (38) PTEN strongly expressed in
62,9% colorectal cancer
PTEN Anti-PTEN antibodies (clone 28116; Santa
Cruz Biotechnology, Santa Cruz, CA,USA
The intensity of tissue staining was
graded semi quantitatively on a 4
point scale (2,+,++,+++). Likewise, the
proportion of cells stained was
assessed on a 4 point scale (1: 0–15%;
2: 25–50%; 3: 50–85% and 4: 85–100%
cell stained).Tissues were classified
into strongly staining and weakly
staining
Sze, KM (39) 47,5% PTEN
underexpression
PTEN Cell signalling biotechnology, Denver;
MA
Western-blot
Terakawa, N (40) 103 endometrial cancers,
36% negative PTEN
PTEN A mouse monoclonal anti PTEN
antibody, PTEN A2B1(Santa Cruz
Biotechnology, Santa Cruz CA,USA)
A positive case was defined as one in
which all of the tumor cells were
stained, a heterogeneous case was
defined as one with both staining and
non-staining tumor cells and a
negative case was defined as one with
no staining of any tumor cells
doi:10.1371/journal.pone.0095219.t002
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selection of patients undergoing experimental treatments with
PI3K inhibitors.
The analysis of studies evaluating downstream components by
IHC showed a significant association with worse survival. These
findings have substantial clinicopathological relevance, as evalu-
ation of the activity of a protein appears more biologically relevant
than the estimation of gene expression. Therefore, assessment of
phosphorylated forms of signaling surrogates such as pS6 or
pAKT may be more precise than evaluation of their total levels.
However, results from these studies were heterogeneous as the
markers evaluated belong to different components of the pathway
(mTORC1 and mTORC2) [24].
These data may have relevance beyond prognostic value.
Among solid tumors where targeted therapy has been developed
against a known oncogene, presence of the oncogene has generally
been associated with worse outcome. This is the case in HER2/
neu over-expressing or amplified breast or gastric cancers or
BRAF-mutated melanoma. Consequently, it is possible that the
effect of drugs targeting the PI3K/AKT/mTOR pathway will
only be seen in patients where biomarkers consistently show a
detrimental clinical outcome. Based on this hypothesis, it would be
expected that PIK3CA mutations may not be associated with
improvement in outcome from drugs targeting the PI3K/AKT/
mTOR pathway. This hypothesis is supported by data in breast
cancer, which show little predictive value of PIK3CA with the
mTOR inhibitor everolimus [15,16,25]. On the other hand, it is
known that not all druggable molecular alterations in cancer are
linked with worse outcome like the expression of estrogen
receptors in breast cancer.
When analyzing the results by tumor type, alterations of the
PI3K/AKT/mTOR pathway in breast cancer were not linked
with worse outcome. However, most of these studies evaluated
PIK3CA mutations. Conversely, studies in gynecological tumors
and gastrointestinal cancers were more enriched in studies
evaluating PTEN and protein markers of ‘‘mTOR or AKT
activation’’; and these were linked with worse outcome. Only
single studies in NSCLC, oropharyngeal and prostate cancers were
available and these showed variable results. These studies were
generally small and consequently reported wide confidence
intervals which crossed the null boundary. Consequently, the
relevance of these results in isolation remains unclear. The
inconsistent measurement of pathway activation means that the
independent effect of PI3K/mTOR/AKT activation in different
tumor types cannot be evaluated with certainty
Our study has limitations. This is a meta-analysis of the
literature and is therefore more likely to be compromised by
selection bias with enrichment for studies reporting positive results.
In addition, there is also substantial intra- and inter-study
heterogeneity including differences in biomarkers of interest and
variability in PIK3CA domain mutations. Despite the use of
statistical methods to reduce the effects of such heterogeneity,
there remains uncertainty regarding the accuracy of the pooled
estimates. Furthermore, hazard ratios were not reported by most
studies and therefore we estimated the odds of death at 5 years
instead. This is a less robust measure for survival, but was the only
feasible method using the available data.
Finally, despite these limitations, results of this study do have
some implications for both clinical and translational research. It is
shown that the activation of the PI3K/AKT/mTOR pathway is
related to poor outcome, and it is particularly relevant in
gastrointestinal and gynecological cancers. In addition, the
evaluation of PTEN levels ideally complemented with concomi-
tant evaluation of the activation status of proteins such as pS6 and
Figure 2. Odds ratio (OR) for 5-year overall survival (OS) in all studies. Forest plots of odds ratios for overall survival at 5 years based on
activation of the PI3K/mTOR/AKT pathway. Odds ratios for each trial are represented by the squares, the size of the square represents the weight of
the trial in the meta-analysis, and the horizontal line crossing the square represents the 95% confidence interval. The diamonds represent the
estimated pooled effect based for each cohort individually (labeled subtotal) and for all cohorts together (labeled total).
doi:10.1371/journal.pone.0095219.g002
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AKT is linked with worse outcome probably identifying tumors
that rely most on the PI3K/AKT/mTOR pathway.
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